Correlation of Specific Inflammatory Markers With the Occurrence of Depression in Patients With Psoriasis and Their Use as Biomarkers for the Diagnosis Of Depression

Autor: Eleni Mitsiou, Aikaterini Kyriakou, Eleni Parlapani, Anastasia Trigoni, Myrto Trakatelli, Zoe Apalla, Dimitrios Sotiriadis, Elizabeth Lazaridou, Aikaterini Patsatsi

Publikováno v: Dermatology Practical & Conceptual, Vol 14, Iss 2 (2024)

Introduction: Psoriasis is a systemic disease of the skin and nails associated with a wide range of comorbidities such as depression, psoriatic arthritis and metabolic syndrome. Objective: The study aimed to examine a potential association between in

Externí odkaz: https://doaj.org/article/48db37d890e94ae6975477e91b95cdb6

Eccrine Poroma: Pathogenesis, New Diagnostic Tools and Association with Porocarcinoma—A Review

Autor: Eirini Kyrmanidou, Christina Fotiadou, Christina Kemanetzi, Myrto-Georgia Trakatelli, Anastasia Trigoni, Aikaterini Patsatsi, Zoe Apalla, Elizabeth Lazaridou

Publikováno v: Diagnostics, Vol 13, Iss 16, p 2689 (2023)

Eccrine poroma (EP) is a relatively rare benign adnexal neoplasm that usually affects elderly patients. Its pathogenesis is still under investigation, but recent gene studies have revealed gene fusions as key incidences resulting in oncogenetic pathw

Externí odkaz: https://doaj.org/article/411defac200d4ba3bb793847c043bea0

External validation of the IHS4-55 in a European antibiotic-treated HS cohort

Autor: Kelsey R. van Straalen, Thrasyvoulos Tzellos, Afsaneh Alavi, Farida Benhadou, Carlos Cuenca-Barrales, Mathilde Daxhelet, Mathieu Daoud, Ourania Efthymiou, Evangelos J. Giamarellos-Bourboulis, Philippe Guillem, Wayne Gulliver, Gregor Borut Ernst Jemec, Alexandros Katoulis, Anke Koenig, Elizabeth Lazaridou, Michelle A. Lowes, Angelo V. Marzano, Łukasz Matusiak, Alejandro Molina-Leyva, Chiara Moltrasio, Andreas Pinter, Concetta Potenza, Errol P. Prens, Jorge Romaní, Ditte Marie L. Saunte, Christopher J Sayed, Nevena Skroza, Dimitra Stergianou, Jacek C. Szepietowski, Anastasia Trigoni, Eva Vilarrasa, Athanassios Kyrgidis, Christos C. Zouboulis, Hessel H. van der Zee

Publikováno v: Dermatology.

Background: Previously, a new dichotomous outcome was developed, calculated as 55% reduction in the International Hidradenitis Suppurativa 4 score (IHS4-55). It was validated in datasets of adalimumab and placebo treated HS patients. External validat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e18956c603850387d57e9aa1766b9677
https://doi.org/10.1159/000528968

A case series of skin manifestations of infective endocarditis in contemporary era: just another book finding or a useful clinical sign?

Autor: Chris Adamopoulos, Christos Gogos, Anastasia Trigoni, Ioannis Styliadis, Vasileios Moschovidis, Vasileios Sachpekidis

Publikováno v: European Heart Journal: Case Reports

Background Infective endocarditis (IE) is a disease of high morbidity and mortality. Infective endocarditis rarely involves skin manifestations in the contemporary era. The identification of typical skin lesions could be helpful in establishing early

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ece94474ad23f0c06c0b1ee0d870062
https://doi.org/10.1093/ehjcr/ytab345

Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa

Autor: José C. Pascual, Christos C. Zouboulis, Isabelle Delorme, Eva Vilarrasa, Ziad Reguiai, Hendrik Hansen, Fernando Alfageme Roldán, Giovanni Damiani, Anastasia Trigoni, Raffaele Dante Caposiena Caro

Publikováno v: DERMATOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Background: Adalimumab is the only approved compound for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS) who did not respond to a systemic classical treatment. Despite its significant short- and long-term efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38c9a3162460978c3c3059659c7d31b4
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4324